Covering: up to 2012 Steroids, a widespread class of natural organic compounds occurring
in animals, plants and fungi, have shown great therapeutic value for a broad array of …

In benign prostatic hyperplasia (BPH) there will be a sudden impact on overall quality of life
of patient. This disease occurs normally at the age of 40 or above and also is associated …

The role of steroidal inhibitors of androgen biosynthesis as potential weapons in the
treatment of prostatic diseases, such as benign prostatic hyperplasia and prostatic cancer …

Insulin resistance is the pathophysiological factor behind the etiology and progression of
Type 2 diabetes mellitus (T2DM), a metabolic syndrome that is continuously increasing in …

Benign prostatic hyperplasia (BPH) is the noncancerous growth of the prostate gland due to
overproliferation of the stromal and glandular elements of the prostate, resulting in the …

Benign prostatic hyperplasia (BPH) is a kind of common noncancerous prostate gland
enlargement with growing tendency in recent years. 5α-reductase is the key enzyme …

Thiazolidinediones (TZDs) have been recently developed to treat diabetic patients that can
reverse insulin resistance by activation of gamma isoform of peroxisome proliferator …

Protein tyrosine phosphatase-1B (PTP-1B) acts as a negative regulator of the insulin
signaling pathway. It is evident from the literature that formylchromone derivatives exhibit …

Azasteroids have been reported as inhibitors of human 5α-reductase enzyme. These were
designed by substitution of one carbon atom of steroidal A ring by heteroatom nitrogen. Due …

In the present study, novel steroidal 17a-substituted 3-cyano-17a-aza-D-homo-3, 5-
androstadien-17-ones (12–19) and 17a-substituted 17-oxo-17a-aza-D-homo-3, 5 …